Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

FDA approves phaseI/II trial of VivoRx's BetaRx-P

Aug. 9, 1996

FDA approves expanded date labelling for LeukoNet

Aug. 9, 1996

Amgen and Kirin sign NESP collaboration

Aug. 9, 1996

Yamanouchi reports squalene synthase inhibitors

Aug. 9, 1996

Alfa Wasserman reveals antioxidant hypolipidemic compounds

Aug. 9, 1996

New formulation of salmon calcitonin undergoes U.S. phase I trial

Aug. 9, 1996

Duphar reports Vitamin D compounds with multiple therapeutic activity

Aug. 9, 1996

Comparative study results of Systen and Menorest

July 26, 1996

Prostaglandin E1 regimen shows positive results for male erectile dysfunction

July 26, 1996

ALT-766: New AGE cross-link breaker from Alteon

July 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.